Emmaus Life Sciences, Inc., announced today that it has entered into an agreement with Kainos Medicine, Inc. (“Kainos”) to lead the preclinical development of Kainos’ patented IRAK4 inhibitor (KM10544) as an anti-cancer drug and further advance the research and development activity currently underway at Kainos.
Read More
Emmaus Life Sciences, Inc., reports that it sold 25,947 boxes of Endari® in 2020 compared to 24,797 boxes in 2019, an increase of 5%.
Read More
Emmaus Life Sciences, Inc., reported today its financial results for the year ended December 31, 2019 and its restated financial results for the year ended December 31, 2018.
Read More
Emmaus Life Sciences, Inc., announced today that it was notified by the Michigan Department of Health and Human Services (MDHHS) that the prior authorization criteria for Endari® was revised after being reviewed by Michigan’s Medicaid Health Plan Common Formulary Workgroup.
Read More
Emmaus Life Sciences, Inc., announced today the launch of the Endari® Support Program.
Read More